Antiplatelet Therapy Clinical Trial
Official title:
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis in China (HITs):a Randomized Clinical Trial
Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01231035 -
REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)
|
N/A | |
Recruiting |
NCT03525145 -
Platelet Reactivity And Clinical ThrombotIC Events Study
|
||
Completed |
NCT01144819 -
Platelet Inhibition in the Acute Phase of STEMI
|
N/A | |
Completed |
NCT03039205 -
Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor
|
Phase 2 | |
Recruiting |
NCT05554822 -
Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study
|
Phase 3 | |
Recruiting |
NCT02099422 -
Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT03758248 -
The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI
|
||
Not yet recruiting |
NCT04060914 -
LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
|
Phase 4 | |
Terminated |
NCT03224923 -
A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)
|
Phase 4 | |
Completed |
NCT03987373 -
DACAB Trial: Follow-up Extension
|